SEC Comment Letter 0000000000-25-002662 to ALX ONCOLOGY HOLDINGS INC (ALXO)
ALX ONCOLOGY HOLDINGS INC
Date: March 11, 2025 · CIK: 0001810182 · Accession: 0000000000-25-002662
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285620
Letter
Re: ALX Oncology Holdings, Inc. Registration Statement on Form S-3 Filed March 6, 2025 File No. 333-285620 Dear Jason Lettmann:
March 11, 2025
Jason Lettmann Chief Executive Officer ALX Oncology Holdings, Inc. 323 Allerton Avenue South San Francisco, CA 94080
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Christina Poulsen
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 11, 2025 Jason Lettmann Chief Executive Officer ALX Oncology Holdings, Inc. 323 Allerton Avenue South San Francisco, CA 94080 Re: ALX Oncology Holdings, Inc. Registration Statement on Form S-3 Filed March 6, 2025 File No. 333-285620 Dear Jason Lettmann: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Christina Poulsen </TEXT> </DOCUMENT>